HER2-Positive Breast Cancer | Clinical

Neratinib/Fulvestrant Shows Modest Anti-Tumor Activity in HER2+ Breast Cancer

April 12, 2021

In the phase 2 MutHER study, the combination of neratinib and fulvestrant demonstrated activity in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, but the clinical benefit rate did not meet the predefined efficacy criteria.

HR Status in HER2+ Breast Cancer Does Not Impact Efficacy of HER2CLIMB Regimen

March 29, 2021

In an interview with Targeted Oncology, Erika P. Hamilton, MD, explained how hormone receptor status in patients with HER2-positive breast cancer was affected by treatment with the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine.

CONTESSA Trial Yields Positive Results for Patients with HER2-Positive Breast Cancer

March 11, 2021

In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA stusy of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer.